<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04924257</url>
  </required_header>
  <id_info>
    <org_study_id>1417/2020</org_study_id>
    <nct_id>NCT04924257</nct_id>
  </id_info>
  <brief_title>ECT vs. Esketamine</brief_title>
  <acronym>ETES</acronym>
  <official_title>Electroconvulsive Therapy vs. Esketamine Nasal Spray in Treatment-resistant Depression: a Longitudinal, Randomized Efficacy Comparison Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment-resistant depression (TRD) is a common cause of disability and one of the most&#xD;
      common psychiatric disorders worldwide.&#xD;
&#xD;
      Electroconvulsive therapy (ECT) is currently the most effective treatment for TRD. Recent&#xD;
      developments showed esketamine to be a rapid-acting and effective antidepressant drug and it&#xD;
      has been hailed as a breakthrough in treating TRD. Common treatment algorithms for TRD list&#xD;
      ECT as a treatment option, but esketamine has not yet found its exact position in those&#xD;
      algorithms.&#xD;
&#xD;
      To the investigators' knowledge, a longitudinal, randomized controlled trial comparing the&#xD;
      efficacy of ECT and intranasal esketamine in TRD patients has not been conducted.&#xD;
      Furthermore, the investigators intend to measure effects of ECT and intranasal esketamine on&#xD;
      brain connectivity and structure, using functional magnetic resonance imaging (fMRI).&#xD;
&#xD;
      In this study, inpatients with TRD at the University Hospital for Psychiatry I, Medical&#xD;
      University Innsbruck, will be randomized to ECT or intranasal esketamine. Short- and&#xD;
      medium-term treatment effects on functional and structural connectivity in the brain will be&#xD;
      determined using fMRI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MADRS score</measure>
    <time_frame>4 weeks</time_frame>
    <description>Reduction of Montgomery-Asberg Depression Rating Scale (MADRS, 0-60 pts.); higher score indicates more depressive symptoms; response to treatment is defined as &gt;50% reduction in score</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Intranasal Esketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ECT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esketamine nasal spray</intervention_name>
    <description>Patients will receive two treatments per week for four weeks (maximum of eight treatment sessions) or until clinical remission (MADRS &lt;10).</description>
    <arm_group_label>Intranasal Esketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Electroconvulsive therapy</intervention_name>
    <description>Patients will receive three treatments per week for four weeks (maximum of 12 ECT treatments) or until clinical remission (MADRS &lt;10).</description>
    <arm_group_label>ECT</arm_group_label>
    <other_name>ECT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. DSM-5 diagnosis of Major Depressive Disorder (MDD) without psychotic features (296.22,&#xD;
             296.23, 296.32, 296.33) made through the Structured Clinical Interview for the DSM-V&#xD;
             (SCID-V).&#xD;
&#xD;
          2. MADRS score ≥ 25&#xD;
&#xD;
          3. Pharmacologically treatment-resistant depressive episode [Stage ≥ II, defined by Thase&#xD;
             &amp; Rush (1997): failure of at least 2 adequate trials of at least 2 distinctly&#xD;
             different classes of antidepressants (≥ 4 weeks each)] (88).&#xD;
&#xD;
          4. Age: 18 - 50 years&#xD;
&#xD;
          5. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participation in another interventional clinical trial&#xD;
&#xD;
          2. Relative contraindications to ECT treatment in accordance with the consensus paper of&#xD;
             the Austrian Society of Psychiatry and Psychotherapy:&#xD;
&#xD;
          3. Patients who meet any exclusion criteria for nasal esketamine treatment as described&#xD;
             in the clinical guidelines&#xD;
&#xD;
          4. Contraindications to the conduction of MRI&#xD;
&#xD;
          5. History of one or more of the following diagnoses (DSM-5):&#xD;
&#xD;
               -  MDD, single or recurrent episode with psychotic features (296.24; 296.34)&#xD;
&#xD;
               -  past or current substance dependence (except caffeine, nicotine) (303.x, 304.x,&#xD;
                  305.x)&#xD;
&#xD;
               -  neurodevelopmental disorders (299.x, 307.x, 314.x, 315.x, 319.x)&#xD;
&#xD;
               -  schizophrenia spectrum and other psychotic disorders (293.x, 295.x, 297.x, 298.x)&#xD;
&#xD;
               -  neurocognitive disorders (290.x, 292.x, 294.x, 331.x).&#xD;
&#xD;
          6. history of ECT (unsuccessful or successful)&#xD;
&#xD;
          7. suicidal tendency requiring admission in a locked ward&#xD;
&#xD;
          8. pregnancy or lactation period&#xD;
&#xD;
          9. lack of anesthetic clearance for any other reason&#xD;
&#xD;
         10. insufficient command of German language.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Julia Dehning, Dr.</last_name>
    <phone>0043 50504 83802</phone>
    <email>julia.dehning@i-med.ac.at</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 7, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2021</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

